| 2025-11-06 |
详情>>
股本变动：
变动后总股本5664.42万股
|
| 2025-11-06 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.41美元,归母净利润-1020.49万美元,同比去年增长-11.88%
|
| 2025-08-13 |
股东大会：
将于2025-09-02召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to our Fourth Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 100,000,000 shares to 1,000,000,000 shares (the “Charter Proposal”);
2.To approve an amendment to the Company’s Fourth Amended and Restated Certificate of Incorporation, or the Certificate of Incorporation, to effect a reverse stock split of the Company’s outstanding common stock, $0.0001 par value per share, at a ratio of not less than 1-for-2 and not more than 1-for-50, such ratio to be determined in the sole discretion of the Company’s Board of Directors, without a corresponding reduction in the Company’s authorized shares, and to be effective upon a date determined by the Board of Directors no later than December 31, 2026 (the “Reverse Stock Split Proposal”);
3.To approve an amendment and restatement of the Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan to increase the number of shares available for issuance under the Plan (the “OIP Proposal”), subject to the prior approval of the Charter Proposal;
4.To approve adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes in favor of the Charter Proposal, the Reverse Stock Split Proposal and/or the OIP Proposal or to establish a quorum (the “Adjournment Proposal”).
|
| 2025-08-07 |
详情>>
业绩披露：
2025年中报每股收益-0.55美元,归母净利润-676.83万美元,同比去年增长-17.98%
|
| 2025-06-18 |
复牌提示：
2025-06-17 12:26:27 停牌，复牌日期 2025-06-17 12:31:27
|
| 2025-05-12 |
股东大会：
将于2025-06-30召开股东大会
会议内容 ▼▲
- 1.To elect the six directors nominated in the attached Proxy Statement to serve as directors until the 2026 Annual Meeting of Stockholders and until their respective successors have been elected and qualified;
2.To approve the issuance of shares of common stock upon exercise of the Series A and B Warrants sold pursuant to the Securities Purchase Agreements entered into on January 27, 2025 in accordance with Nasdaq listing rules;
3.To ratify the appointment of Cherry Bekaert, LLP as the independent registered public accounting firm of Processa Pharmaceuticals, Inc. for the fiscal year ending December 31, 2025;
4.To approve, by advisory vote, the compensation of our 2025 named executive officers;
5.To transact such other business as properly may come before the Annual Meeting or any adjournments or postponements thereof.
|
| 2025-05-08 |
详情>>
业绩披露：
2025年一季报每股收益-0.3美元,归母净利润-283.44万美元,同比去年增长-3.96%
|
| 2025-04-11 |
详情>>
内部人交易：
Bigora Sian共交易2笔
|
| 2025-03-20 |
详情>>
业绩披露：
2024年年报每股收益-3.87美元,归母净利润-1185.01万美元,同比去年增长-6.55%
|
| 2024-10-30 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-3.13美元,归母净利润-912.14万美元,同比去年增长-4.64%
|
| 2024-08-13 |
详情>>
业绩披露：
2024年中报每股收益-2.11美元,归母净利润-573.67万美元,同比去年增长13.53%
|
| 2024-05-10 |
详情>>
业绩披露：
2024年一季报每股收益-1.11美元,归母净利润-272.64万美元,同比去年增长32.21%
|
| 2024-04-29 |
股东大会：
将于2024-06-28召开股东大会
会议内容 ▼▲
- 1.To elect the six directors nominated in the attached Proxy Statement to serve as directors until the 2025 Annual Meeting of Stockholders and until their respective successors have been elected and qualified;
2.To approve an amendment and restatement of the Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan to increase the number of shares available for issuance under the Plan by 500,000 shares;
3.To ratify the appointment of BD & Company, Inc. as the independent registered public accounting firm of Processa Pharmaceuticals, Inc. for the fiscal year ending December 31, 2024;
4.To approve, by advisory vote, the compensation of our named executive officers;
5.To transact such other business as properly may come before the Annual Meeting or any adjournments or postponements thereof.
|
| 2024-03-29 |
详情>>
业绩披露：
2023年年报每股收益-8.48美元,归母净利润-1112.15万美元,同比去年增长59.45%
|
| 2024-01-22 |
详情>>
拆分方案：
每20.0000合并分成1.0000股
|
| 2023-11-13 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-0.34美元,归母净利润-871.66万美元,同比去年增长39.52%
|
| 2023-10-05 |
股东大会：
将于2023-11-14召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to the Company’s Fourth Amended and Restated Certificate of Incorporation, or the Certificate of Incorporation, to effect a reverse stock split of the Company’s outstanding common stock, $0.0001 par value per share, at a ratio of not less than 1-for-5 and not more than 1-for-30, such ratio to be determined in the sole discretion of the Company’s Board of Directors, without a corresponding reduction in the Company’s authorized shares, and to be effective upon a date determined by the Board of Directors no later than March 18, 2024 (the “Reverse Stock Split Proposal”).
2.To approve adjournment of the Special Meeting to a later date or dates, if necessary or appropriate, to solicit additional proxies if there are insufficient votes in favor of the Reverse Stock Split Proposal or to establish a quorum (the “Adjournment Proposal”).
|
| 2023-08-10 |
详情>>
业绩披露：
2023年中报每股收益-0.27美元,归母净利润-663.46万美元,同比去年增长20.94%
|
| 2023-05-01 |
股东大会：
将于2023-06-27召开股东大会
会议内容 ▼▲
- 1.To elect the six directors nominated in the attached Proxy Statement to serve as directors until the 2024 Annual Meeting of Stockholders and until their respective successors have been elected and qualified;
2.To approve an amendment to our Fourth Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 50,000,000 shares to 100,000,000 shares;
3.To ratify the appointment of BD & Company, Inc. as the independent registered public accounting firm of Processa Pharmaceuticals, Inc. for the fiscal year ending December 31, 2023;
4.To approve, by advisory vote, the compensation of our named executive officers;
5.To transact such other business as may properly come before the Annual Meeting or any adjournments or postponements thereof.
|
| 2023-03-30 |
财报披露：
美东时间 2023-03-30 盘后发布财报
|
| 2022-05-31 |
股东大会：
将于2022-07-11召开股东大会
会议内容 ▼▲
- 1.To elect the five directors nominated in the attached Proxy Statement to serve as directors until the 2023 Annual Meeting of Stockholders and until their respective successors have been elected and qualified;
2.To approve, by advisory vote, the compensation of our named executive officers;
3.To approve an amendment and restatement of the Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan to increase the number of shares available for issuance under the 2019 Omnibus Incentive Plan by 3,000,000 shares;
4.To ratify the appointment of BD & Company, Inc. as the independent registered public accounting firm of Processa Pharmaceuticals, Inc. for the fiscal year ending December 31, 2022;
5.To transact such other business as properly may come before the Annual Meeting or any adjournments or postponements thereof.
|
| 2021-09-20 |
股东大会：
将于2021-11-03召开股东大会
会议内容 ▼▲
- 1.to approve an amendment to our Fourth Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 30,000,000 shares to 50,000,000 shares;
2.to approve an adjournment of the Special Meeting, if the Board of Directors determines it to be necessary or appropriate, if a quorum is present, to solicit additional proxies if there are not sufficient votes in favor of Proposal 1;
3.to transact such other business as may properly come before the meeting or any adjournments or postponements of the meeting.
|
| 2021-09-06 |
温馨提示：
美股因劳工节，9月6日休市一天
|
| 2021-04-22 |
股东大会：
将于2021-06-08召开股东大会
会议内容 ▼▲
- 1.To elect the five directors nominated in the attached Proxy Statement to serve as directors until the 2022 Annual Meeting of Stockholders and until their respective successors have been elected and qualified;
2.To approve an advisory vote on executive compensation;
3.To conduct an advisory vote on the frequency of future advisory votes on executive compensation;
4.To approve an amendment and restatement of the Processa Pharmaceuticals, Inc. 2019 Omnibus Incentive Plan to increase the number of shares available for issuance under the 2019 Omnibus Incentive Plan by 2,500,000 shares;
5.To ratify the appointment of BD & Company Inc. as the independent registered public accounting firm of Processa Pharmaceuticals, Inc. for the fiscal year ending December 31, 2021;
6.To transact such other business as properly may come before the Annual Meeting or any adjournments or postponements thereof.
|